172 related articles for article (PubMed ID: 31612195)
1. The Th1 chemokine MIG in Graves' ophthalmopathy.
Gonnella D
Clin Ter; 2019; 170(5):e368-e372. PubMed ID: 31612195
[TBL] [Abstract][Full Text] [Related]
2. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
3. The Th1 chemokine MIG in Graves' Disease: a narrative review of the literature.
Giusti C
Clin Ter; 2019; 170(4):e285-e290. PubMed ID: 31304517
[TBL] [Abstract][Full Text] [Related]
4. Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity.
Fallahi P; Ferrari SM; Corrado A; Giuggioli D; Ferri C; Antonelli A
Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(2):95-101. PubMed ID: 24953644
[TBL] [Abstract][Full Text] [Related]
5. Sjögren syndrome and MIG.
Ruffilli I
Clin Ter; 2019; 170(6):e478-e482. PubMed ID: 31696913
[TBL] [Abstract][Full Text] [Related]
6. [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease and Graves'ophthalmopathy].
Di Domenicantonio A; Politti U; Giuggioli D; Antonelli A; Ferri C; Fallahi P
Clin Ter; 2014; 165(3):e230-6. PubMed ID: 24999581
[TBL] [Abstract][Full Text] [Related]
7. MIG in autoimmune thyroiditis: review of the literature.
Pezzano M
Clin Ter; 2019; 170(4):e295-e300. PubMed ID: 31304519
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapies for Thyroid Autoimmune Diseases.
Fallahi P; Ferrari SM; Elia G; Nasini F; Colaci M; Giuggioli D; Vita R; Benvenga S; Ferri C; Antonelli A
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):853-61. PubMed ID: 26900630
[TBL] [Abstract][Full Text] [Related]
9. β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Pupilli C; Bernini G; Sellari-Franceschini S; Gelmini S; Ferrannini E; Fallahi P
J Endocrinol; 2012 May; 213(2):183-91. PubMed ID: 22378921
[TBL] [Abstract][Full Text] [Related]
10. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
[TBL] [Abstract][Full Text] [Related]
12. [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease].
Mancusi C; Di Domenicantonio A; Politti U; Giuggioli D; Antonelli A; Ferri C; Fallahi P
Clin Ter; 2014; 165(2):e174-80. PubMed ID: 24770830
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes.
Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Gelmini S; Minuto M; Pupilli C; Miccoli P; Sellari-Franceschini S; Ferrannini E; Fallahi P
Mol Cell Endocrinol; 2012 Feb; 349(2):255-61. PubMed ID: 22101320
[TBL] [Abstract][Full Text] [Related]
14. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
[TBL] [Abstract][Full Text] [Related]
16. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ.
Antonelli A; Ferrari SM; Corrado A; Franceschini SS; Gelmini S; Ferrannini E; Fallahi P
Autoimmun Rev; 2014 Nov; 13(11):1160-6. PubMed ID: 25172242
[TBL] [Abstract][Full Text] [Related]
17. Dermatomyositis and MIG.
Ragusa F
Clin Ter; 2019; 170(2):e142-e147. PubMed ID: 30993311
[TBL] [Abstract][Full Text] [Related]
18. Sjögren's syndrome and chemokines.
Ruffilli I
Clin Ter; 2014; 165(6):e464-9. PubMed ID: 25524206
[TBL] [Abstract][Full Text] [Related]
19. Chemokines in thyroid autoimmunity.
Ferrari SM; Paparo SR; Ragusa F; Elia G; Mazzi V; Patrizio A; Ghionzoli M; Varricchi G; Centanni M; Ulisse S; Antonelli A; Fallahi P
Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101773. PubMed ID: 36907786
[TBL] [Abstract][Full Text] [Related]
20. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells.
Ranjbaran H; Wang Y; Manes TD; Yakimov AO; Akhtar S; Kluger MS; Pober JS; Tellides G
Circulation; 2006 Sep; 114(12):1293-300. PubMed ID: 16940188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
